Drug intelligence / Profile preview

DPI-521CG

Development stage: Preclinical
Lead developer: Defender Pharmaceuticals
Modality: Small Molecules
Administration: Intranasal

Overview

DPI-521CG is a preclinical-stage small molecule muscarinic acetylcholine receptor antagonist being developed by Defender Pharmaceuticals. It is designed as a chemical countermeasure, utilizing an intranasal delivery route to provide a rapid-acting treatment against cholinergic overstimulation, such as that caused by organophosphate nerve agents. The drug is part of a platform of scopolamine-related compounds optimized for intranasal administration to ensure ease of use and rapid systemic absorption in emergency or military settings.

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on DPI-521CG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPI-521CG.

Explore the full profile